JNJ catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 23, 2026Sponsor estimate | NCT07735793A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in KoreaJanssen Korea, Ltd., Korea · Urinary Bladder Neoplasms | JNJLead | No phase registered | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 23, 2026Sponsor estimateNo phase registeredNCT07735793A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in KoreaJanssen Korea, Ltd., Korea · Urinary Bladder NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT00825929Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.Radboud University Medical Center · HIV Infections
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT03903835ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerKarolinska Institutet · Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingJNJCollaboratorAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06651489Efficacy of Guselkumab in Treating Hailey Hailey DiseaseYale University · Hailey Hailey DiseaseRecruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT06816992ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCORIC Pharmaceuticals · Solid TumorsRecruitingORICLeadJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 2/Phase 3NCT05327114Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Janssen Research & Development, LLC · Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1NCT07223125A Study of JNJ-89862175 for Treatment of Advanced Solid TumorsJanssen Research & Development, LLC · Advanced-stage Solid TumorsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT06067269Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer...Jonsson Comprehensive Cancer Center · Prostate AdenocarcinomaRecruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT06559306Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia...Janssen Research & Development, LLC · Depressive Disorder, MajorRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT05004727Multi-Center PAMPA StudyNYU Langone Health · PsoriasisRecruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06085586Fibulink Syndesmosis Repair System With Early Full-Weight BearingMaimonides Medical Center · Ankle FracturesRecruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06217107Wellness & Workforce Solution for Lupus/Lupus NephritisMorehouse School of Medicine · Lupus NephritisRecruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT06827860Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early RelapseLarysa Sanchez · Multiple Myeloma in Relapse | JNJCollaborator | Phase 2 | Recruiting | Locked | Locked | Locked |
| Jan 7, 2027Sponsor estimate | NCT07319871A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate CancerJanssen Research & Development, LLC · Prostatic Neoplasms | JNJLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT05179876A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionActelion · Hypertension, Pulmonary | JNJLead | Phase 3 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimatePhase 2NCT06827860Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early RelapseLarysa Sanchez · Multiple Myeloma in RelapseRecruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 7, 2027Sponsor estimatePhase 1NCT07319871A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 3NCT05179876A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionActelion · Hypertension, PulmonaryRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 16, 2027Sponsor estimate | NCT07669077A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating WomenJanssen Research & Development, LLC · Healthy | JNJLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 16, 2027Sponsor estimatePhase 1NCT07669077A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating WomenJanssen Research & Development, LLC · HealthyRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.